Hoffmann-La Roche (Roche) develops, manufactures and deliver innovative therapeutics and diagnostic instruments and tests.
The company operates through two business segments: Pharmaceuticals and Diagnostics. Pharmaceuticals division is further categorized on the basis of therapeutic areas into oncology, immunology, infectious diseases, ophthalmology, neuroscience and other therapeutic areas. The company recorded sales of CHF 48.1 billion, an increase by 5% which can be attributed enhanced sales in oncology and immunology portfolios, especially the medicines for HER2-positive breast cancer, and by the Diagnostics business. The earnings per share in 2015 was CHF 10.42. The total pharmaceuticals sales in 2015 was CHF 37.3 billion accounting for 77.5% of the total sales. The oncology and immunology segment accounted for nearly 80% of the total pharmaceuticals sale in 2015. The pharmaceutical sales of the company in 2015 increased by 5% from 2014, due to strong growth in oncology product such as Herceptin, Avastin, Perjeta, MabThera/Rituxan, Kadcyla and immunology products including Esbriet, Actemra/RoActemra.
Roche stood at CHF 37.5 billion in 2016, total increase of 6%, as compared to 2015 fiscal nine months sales of CHF 35.5 billion. The fiscal third quarter (Q3) sales were CHF 12.5 billion an increase of 3% compared to 2015 Q3 sales. The company recorded a total pharmaceutical sales of fiscal nine months at CHF 29.1 billion in 2016 which is 5% higher as compared to the same period in 2015, driven by demand for breast cancer medicines Perjeta and Herceptin as well as for Actemra/RoActemra for rheumatoid arthritis. Furthermore, the launch of medicines Tecentriq in bladder cancer and Alecensa in lung cancer have also contributed to the enhanced growth. Q3 pharmaceutical sales stood at CHF 9.7 billion an increase of 9% as compared to the same period a year ago. Contributors to the growth were strong sales of oncology and immunology medicines along with positive currency impact.
Check out all the other “Pharma Companies at a Glance” already available. Many more coming next on IgeaHub.